← C4 Therapeutics, Inc. (CCCC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
C4 Therapeutics, Inc. (CCCC)
Biological Products, (No Diagnostic Substances) · market cap $385M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
C4 Therapeutics (CCCC) is a small-cap biotech (~$449M market cap, 110 employees) focused on targeted protein degradation, with its lead asset cemsidomide in Phase 2 trials for multiple myeloma. The company carries a 6.1-month cash runway on $61.3M, making near-term financing an acute structural concern, with elevated dilution risk (31% flagged) and a 22.6% short float underscoring market skepticism.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-01-01Data Readoutimp 3/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Cemsidomide | Phase 2 | Multiple Myeloma |
Price & technical context
3-month
-27.0%
6-month
+16.3%
12-month
+41.4%
52-wk range
$1.71–$4.67
vs 50-day MA
-13.8%
vs 200-day MA
+0.9%
Realized vol
80.1%
Max drawdown
-84.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CCCC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.